Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that acts selectively at the ghrelin receptor (GHS-R1a). It is studied for its stimulation of pulsatile growth hormone release and is supplied strictly for laboratory research use.

What is the CJC-1295/Ipamorelin research pairing?

The pairing combines a GHRH-pathway analog with a ghrelin-receptor agonist — two complementary GH-release signaling pathways. It is one of the most referenced combinations in the growth-hormone-axis research literature.

What purity standard applies to Ipamorelin?

PX1 specifies ≥ 99% purity by HPLC with identity confirmed by LC-MS. Every batch includes a lot-specific Certificate of Analysis and endotoxin screening.

Is Ipamorelin approved for human use?

No. Ipamorelin is an unapproved research compound. All PX1 material is strictly for laboratory research use only and not for human or veterinary administration.

Compound Monograph — PX-IPA

Ipamorelin

Q: What makes Ipamorelin different from other secretagogues?

Selectivity. Published comparative work describes GH-release activity without the significant cortisol, prolactin, or appetite effects documented for earlier secretagogues such as GHRP-6 in the same model systems.

Pentapeptide growth-hormone secretagogue — selective ghrelin-receptor agonist

For laboratory research use only. Not for human or veterinary use.

Compound data

Compound class: Growth-hormone secretagogue (GHS) pentapeptide
Structure: 5-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2)
Molecular formula: C38H49N9O5
Molar mass: ≈ 711.9 g/mol
CAS number: 170851-70-4
Receptor target: Ghrelin / growth-hormone secretagogue receptor (GHS-R1a)
Presentation: Lyophilized powder — 5mg and 10mg vials
Purity specification: ≥ 99% by HPLC, identity confirmed by LC-MS

Overview

Ipamorelin is a synthetic pentapeptide and one of the most studied compounds in the growth-hormone secretagogue class. It acts as a selective agonist at the ghrelin/growth-hormone secretagogue receptor (GHS-R1a), stimulating pulsatile growth hormone release from the anterior pituitary in published models.

Its defining characteristic in the literature is selectivity: published comparative work describes Ipamorelin's GH-release activity without the significant cortisol, prolactin, or appetite effects documented for earlier secretagogues such as GHRP-6 and hexarelin in the same model systems.

Mechanism in the research literature

GHS-R1a receptor agonism

Ipamorelin binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, stimulating pulsatile endogenous growth hormone release in published models. This is the same receptor targeted by the endogenous hormone ghrelin.

Selectivity profile

Published comparative studies describe Ipamorelin as not significantly stimulating ACTH, cortisol, or prolactin at GH-releasing doses in the model systems examined — a selectivity profile that distinguishes it from first-generation secretagogues in the research literature.

Synergy context with GHRH analogs

Published research examines complementary signaling between ghrelin-receptor and GHRH-receptor pathways. This dual-pathway context underlies research pairings such as the CJC-1295/Ipamorelin combination studied in the secretagogue literature.

Published research summary

Published phase-trial work examined Ipamorelin in gastrointestinal-motility model endpoints, establishing its pharmacokinetic and tolerability characterization in study settings.
Comparative secretagogue studies document its selective GH-release profile relative to GHRP-6, GHRP-2, and hexarelin in model systems.
The CJC-1295/Ipamorelin combination is among the most referenced secretagogue pairings in the GH-axis research literature.
Every PX-IPA batch is released against ≥ 99% HPLC purity with LC-MS identity confirmation and a lot-specific Certificate of Analysis.

Handling, reconstitution & storage

Storage (lyophilized): -20 °C long term; 2–8 °C short term; protect from light
Reconstitution: Bacteriostatic water down the vial wall; swirl gently until dissolved
Example ratio: 5mg vial + 2.0 mL diluent = 2.5 mg/mL (10 units = 250 mcg)
Stability (reconstituted): Reference ≈ 28–30 days refrigerated at 2–8 °C with bacteriostatic water
Freeze/thaw: Avoid repeated cycling of reconstituted solutions

Frequently asked questions

Related resources

CJC-1295 / Ipamorelin research hub Ipamorelin peptide page Peptide reconstitution calculator

Research use only. Ipamorelin (PX-IPA) is supplied exclusively as a laboratory research compound. It is not a drug, food, or cosmetic, and it is not intended for human or veterinary administration, diagnostic use, or household use. Statements on this page summarize published scientific literature for reference purposes and do not constitute medical advice or health claims. All PX1 Research batches ship with lot-specific Certificates of Analysis confirming ≥ 99% purity by HPLC and identity by LC-MS.